Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BHQ880 · 3 trials · 4 indications
Time to first SRE from randomization
| Arm | Type | Description |
|---|---|---|
| BHQ880 + bortezomib and dexamethasone | EXPERIMENTAL | - |
| BHQ880 Placebo + bortezomib and dexamethasone | PLACEBO_COMPARATOR | - |
| BHQ880 | EXPERIMENTAL | - |
| BHQ880 + zoledronic acid | EXPERIMENTAL | BHQ880 3-40 mg/kg in combination with zoledronic acid 4 mg on day 1 of a 28-day cycle. |
| Name | Type | Description |
|---|---|---|
| BHQ880 | DRUG | - |
| BHQ880 Placebo | DRUG | Intravenous infusion |
| bortezomib | DRUG | intravenous injection |
| dexamethasone | DRUG | Oral |
| Zoledronic acid | DRUG | - |
Inclusion Criteria: 1. Confirmed diagnosis of multiple myeloma 2. Life expectancy of more than 6 months in the absence of intervention 3. Must not have received previous or be receiving current antimyeloma therapies 4. Renal insufficiency 5. Recovered from the effects of any prior surgery or radiot...
Top 20 of 25 competitors
BHQ880 is an investigational medicine being studied in multiple myeloma, including smoldering multiple myeloma and myeloma bone disease. It has been tested in patients with untreated multiple myeloma and renal insufficiency as well. It is not an approved therapy and remains in clinical development.
BHQ880 targets DKK1, a protein involved in bone metabolism and myeloma bone disease. BHQ880 is a small molecule inhibitor of DKK1. By acting on this target, it is designed to interfere with DKK1 activity in multiple myeloma and related bone complications.
BHQ880 is developed by Novartis AG, which trades under the ticker NVS. Novartis sponsored the clinical studies of BHQ880 in multiple myeloma, smoldering multiple myeloma, and myeloma bone disease.
BHQ880 has been studied in Phase 2 clinical development. It is investigational and has not been approved by the FDA. The Phase 2 studies in multiple myeloma and smoldering multiple myeloma have been completed, and no trials are currently active.
BHQ880 has been evaluated in three completed trials. NCT01302886 studied high risk smoldering multiple myeloma, NCT01337752 studied untreated multiple myeloma with renal insufficiency, and NCT00741377 tested BHQ880 with zoledronic acid in relapsed or refractory myeloma bone disease.